Sun Pharma Advanced Research Company Ltd's Q3FY25 Quarterly Results

Result Summary

• Sun Pharma Advanced Research Company Ltd reported a 17.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a decline of 25.4%.
• Its expenses for the quarter were down by 21.3% QoQ and 21.2% YoY.
• The net profit decreased 25.9% QoQ and decreased 20.2% YoY.
• The earnings per share (EPS) of Sun Pharma Advanced Research Company Ltd declined at 2.5 during Q3FY25.

Financial Statments for Q3FY25

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Sun Pharma Advanced Research Company Ltd (SPARC) is a pharmaceutical research and development company that focuses on innovative drug delivery systems, new chemical entities, and biologics. As a part of the broader pharmaceutical industry, SPARC is engaged in the development of novel therapeutics and aims to address unmet medical needs in various therapeutic areas. The company is known for its focus on creating differentiated products that leverage advanced technologies in drug delivery and formulation. Recent developments from SPARC include advancements in their pipeline of drug candidates, although specific details of these developments are not provided in the current data set.

Revenue

In the third quarter of fiscal year 2025 (Q3FY25), Sun Pharma Advanced Research Company Ltd reported a total income of ₹15.10 crores. This represents a quarter-over-quarter (QoQ) increase of 17.1% compared to the previous quarter (Q2FY25), where the total income was ₹12.90 crores. However, the year-over-year (YoY) comparison shows a decline of 25.4% from the total income of ₹20.25 crores reported in Q3FY24. These figures highlight the fluctuations in revenue, which may be attributed to various factors affecting the company's operations and market conditions during these periods.

Profitability

The profitability metrics for Sun Pharma Advanced Research Company Ltd in Q3FY25 show a significant improvement compared to the previous quarter. The company posted a loss before tax of ₹79.44 crores, which is a 25.9% reduction in losses from Q2FY25's loss of ₹107.17 crores. Similarly, the profit after tax for Q3FY25 was a loss of ₹79.51 crores, also showing a 25.9% improvement from the previous quarter's loss of ₹107.33 crores. When compared year-over-year, the loss before tax decreased by 20.3% from Q3FY24's loss of ₹99.65 crores, and the loss after tax showed a similar decrease of 20.2%. Despite these improvements, the company remains in a loss-making position for the reported periods.

Operating Metrics

The operating expenses for Q3FY25 amounted to ₹94.54 crores, marking a 21.3% decrease from Q2FY25's expenses of ₹120.07 crores, and a 21.2% decrease from Q3FY24's expenses of ₹119.90 crores. This reduction in expenses is a notable aspect of the company's operational performance. The earnings per share (EPS) for Q3FY25 were reported at a negative ₹2.50, which is an improvement from the negative ₹3.30 reported in Q2FY25 and the negative ₹3.10 reported in Q3FY24. This indicates a reduction in losses attributable to shareholders over the quarters and the year. The tax expense for Q3FY25 was minimal at ₹0.07 crores, showing a reduction from both the previous quarter and the same quarter last year, where the amounts were ₹0.16 crores and ₹0.00 crores, respectively.